J H W Distler

Summary

Affiliation: University of Erlangen-Nuremberg
Country: Germany

Publications

  1. pmc Platelet-derived serotonin links vascular disease and tissue fibrosis
    Clara Dees
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    J Exp Med 208:961-72. 2011
  2. pmc Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
    Alfiya Akhmetshina
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    Nat Commun 3:735. 2012
  3. pmc Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis
    María Teruel
    Instituto de Parasitologia y Biomedicina Lopez Neyra, IPBLN CSIC, Avda, del Conocimiento s n, 18010, Granada, SpainArmilla Granada, Spain
    Arthritis Res Ther 14:R154. 2012
  4. doi request reprint Autophagy regulates TNFα-mediated joint destruction in experimental arthritis
    Neng Yu Lin
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 72:761-8. 2013
  5. ncbi request reprint Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis
    Marlene Kramer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Ulmenweg 18, Erlangen D 91054, Germany
    Ann Rheum Dis 72:614-20. 2013
  6. ncbi request reprint Activation of pregnane X receptor inhibits experimental dermal fibrosis
    Christian Beyer
    Department of Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Ulmenweg 18, Erlangen D 91054, Germany
    Ann Rheum Dis 72:621-5. 2013
  7. doi request reprint Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1
    Katrin Palumbo-Zerr
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:2051-4. 2012
  8. doi request reprint Pomalidomide is effective for prevention and treatment of experimental skin fibrosis
    Simon Weingärtner
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:1895-9. 2012
  9. doi request reprint Inhibition of sumoylation prevents experimental fibrosis
    Aisa Khodzhigorova
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:1904-8. 2012
  10. doi request reprint Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis
    Christian Beyer
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:1019-26. 2012

Collaborators

Detail Information

Publications30

  1. pmc Platelet-derived serotonin links vascular disease and tissue fibrosis
    Clara Dees
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    J Exp Med 208:961-72. 2011
    ..These findings suggest that 5-HT/5-HT(2B) signaling links vascular damage and platelet activation to tissue remodeling and identify 5-HT(2B) as a novel therapeutic target to treat fibrotic diseases...
  2. pmc Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
    Alfiya Akhmetshina
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    Nat Commun 3:735. 2012
    ..These findings demonstrate that canonical Wnt signalling is necessary for TGF-β-mediated fibrosis and highlight a key role for the interaction of both pathways in the pathogenesis of fibrotic diseases...
  3. pmc Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis
    María Teruel
    Instituto de Parasitologia y Biomedicina Lopez Neyra, IPBLN CSIC, Avda, del Conocimiento s n, 18010, Granada, SpainArmilla Granada, Spain
    Arthritis Res Ther 14:R154. 2012
    ..The aim of the present study was to investigate the possible role of CD40 and CD40 ligand (CD40LG) genes in the susceptibility and phenotype expression of systemic sclerosis (SSc)...
  4. doi request reprint Autophagy regulates TNFα-mediated joint destruction in experimental arthritis
    Neng Yu Lin
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 72:761-8. 2013
    ..Dysregulation of autophagic pathways has recently been implicated in the pathogenesis of various diseases. Here, we investigated the role of autophagy during joint destruction in arthritis...
  5. ncbi request reprint Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis
    Marlene Kramer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Ulmenweg 18, Erlangen D 91054, Germany
    Ann Rheum Dis 72:614-20. 2013
    ..However, histone methylation has not been investigated so far. We therefore aimed to evaluate the role of the trimethylation of histone H3 on lysine 27 (H3K27me3) on fibroblast activation and fibrosis...
  6. ncbi request reprint Activation of pregnane X receptor inhibits experimental dermal fibrosis
    Christian Beyer
    Department of Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Ulmenweg 18, Erlangen D 91054, Germany
    Ann Rheum Dis 72:621-5. 2013
    ..To assess the antifibrotic effects of pregnane X receptors (PXRs) in experimental dermal fibrosis...
  7. doi request reprint Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1
    Katrin Palumbo-Zerr
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:2051-4. 2012
    ..Selective targeting of the cannabinoid receptors CB1 and CB2 by synthetic compounds has revealed opposing roles of both receptors in fibrosis...
  8. doi request reprint Pomalidomide is effective for prevention and treatment of experimental skin fibrosis
    Simon Weingärtner
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:1895-9. 2012
    ..Here, we investigated the antifibrotic effects of pomalidomide, an analogue of thalidomide with potent immunomodulatory effects, in preclinical models of skin fibrosis...
  9. doi request reprint Inhibition of sumoylation prevents experimental fibrosis
    Aisa Khodzhigorova
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:1904-8. 2012
    ..First epigenetic modifications have recently been shown to contribute to activation of SSc fibroblasts. Here, we investigated inhibition of sumoylation as a novel antifibrotic approach...
  10. doi request reprint Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis
    Christian Beyer
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:1019-26. 2012
    ..Stimulators of soluble guanylate cyclase (sGC) are vasoactive drugs that are currently being evaluated in phase III clinical trials for pulmonary arterial hypertension...
  11. doi request reprint The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis
    Gerhard Kronke
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:1081-7. 2012
    ..Understanding endogenous mechanisms, which counteract fibrosis, may yield new therapeutic approaches. Lipoxins are highly potent lipid mediators, which have recently been found to be decreased in SSc...
  12. doi request reprint Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis
    Angelika Horn
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:785-9. 2012
    ..Effective antifibrotic treatments are not available. Here, the authors investigated inhibition of hedgehog signalling by targeting Smoothened (Smo) as a novel antifibrotic approach...
  13. pmc β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis
    Christian Beyer
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:761-7. 2012
    ..catenin is an integral part of adherens junctions and a central component of canonical Wnt signaling. Here, the authors addressed the role of β-catenin in fibroblasts for the development of SSc dermal fibrosis...
  14. doi request reprint Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis
    Nicole Reich
    Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:737-45. 2012
    ..This study analysed the antifibrotic effects of the selective c-Jun N-terminal kinase (JNK) inhibitor, CC-930, which recently entered first clinical trials as a novel antifibrotic approach...
  15. pmc Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis
    Christian Beyer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Res Ther 11:220. 2009
    ..Altogether, hypoxia might play a central role in pathogenesis of SSc by augmenting vascular disease and tissue fibrosis...
  16. doi request reprint Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway
    Christina Bergmann
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:2191-8. 2011
    ..A study was undertaken to define the role of GSK-3 in fibroblast activation and in experimental models of systemic sclerosis (SSc)...
  17. doi request reprint Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease
    Jörg H W Distler
    Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1197-202. 2011
    ..Vascular disease is common in mixed connective tissue disease (MCTD). The aim of the present study was to investigate, whether dysbalance of angiogenic and angiostatic factors occurs in MCTD...
  18. doi request reprint [Primary and secondary Raynaud's phenomenon]
    J H W Distler
    Medizinische Klinik 3 und Institut für klinische Immunologie, Universitat Erlangen Nurnberg, Universitätsstrasse 29, 91054 Erlangen
    Z Rheumatol 67:211-7; quiz 218-9. 2008
    ..Drug therapies with proven efficacy include calcium channel blockers, prostacyclin analogues, fluoxetine, losartan and sildenafil...
  19. doi request reprint Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis
    J H W Distler
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Germany
    Rheumatology (Oxford) 47:v10-1. 2008
    ..Based on the promising pre-clinical data, imatinib is currently evaluated in clinical trials for the treatment of fibrosis in SSc and trials with other tyrosine kinase inhibitors are in preparation...
  20. doi request reprint Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis
    J H W Distler
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, G1054 Erlangen, Germany
    Rheumatology (Oxford) 48:98-103. 2009
    ..Antagonists against the receptor CCR2 are currently tested in clinical trials of a variety of diseases and also represent interesting candidates for target-directed therapy in SSc...
  21. doi request reprint Induction of apoptosis in circulating angiogenic cells by microparticles
    Jörg H W Distler
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 63:2067-77. 2011
    ..The aim of this study was to analyze whether microparticles might link pathologic activation and apoptosis of ECs with reduced numbers of CACs...
  22. ncbi request reprint Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique
    Joerg H W Distler
    Department of Rheumatology, University of Erlangen Nuremberg, Germany
    Clin Exp Rheumatol 29:S40-5. 2011
    ..To obtain experiences and expert opinion on treatment of SSc patients with TNF-α antagonists...
  23. doi request reprint Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies
    J H W Distler
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 69:i48-51. 2010
    ..Until the results of these trials are available, we discourage off-label use of Imatinib in single patients...
  24. ncbi request reprint Angiogenesis and vasculogenesis in systemic sclerosis
    J H W Distler
    Department of Internal Medicine III, University of Erlangen Nuremberg, Germany
    Rheumatology (Oxford) 45:iii26-7. 2006
    ..Besides defective angiogenesis, recent studies suggest that vasculogenesis is also impaired in SSc patients with reduced numbers and functional defects of endothelial progenitor cells...
  25. doi request reprint EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells
    J H W Distler
    Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 68:163-8. 2009
    ..In summary, the EUSTAR recommendations will help to unify EPC research and allow better comparison between the results of different studies...
  26. ncbi request reprint [Vascular changes in the pathogenesis of systemic sclerosis]
    J H W Distler
    Department of Internal Medicine III, University of Erlangen Nuremberg, Germany
    Z Rheumatol 63:446-50. 2004
    ..In addition to the impaired angiogenesis, defective vasculogenesis might contribute to the vascular symptoms of SSc...
  27. doi request reprint Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis
    Clara Dees
    Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1304-10. 2011
    ..Dermal fibroblasts from patients with systemic sclerosis (SSc) release excessive amounts of collagen resulting in tissue fibrosis. The molecular mechanisms underlying this pathological activation are incompletely understood...
  28. doi request reprint The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis
    Katrin Palumbo
    Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1320-6. 2011
    ..Here, the role of JunD, a member of the activator protein 1 (AP-1) family of transcription factors, as a downstream mediator of TGFβ signalling in systemic sclerosis (SSc), was investigated...
  29. ncbi request reprint [Angiogenesis. Possibilities for therapeutic intervention in rheumatic diseases]
    B Maurer
    Zentrum für Experimentelle Rheumatologie, Universitatsspital Zurich, Gloriastrasse 25, 8091 Zurich
    Z Rheumatol 66:304, 306-10. 2007
    ..Two examples for pathologically disturbed angiogenesis, rheumatoid arthritis and systemic sclerosis, are discussed in this review with respect to therapeutic options...
  30. ncbi request reprint Angiogenic and angiostatic factors in the molecular control of angiogenesis
    J H W Distler
    WHO Collaborating Center for Molecular Biology and Novel Therapeutic Strategies for Rheumatic Diseases, University Hospital, Zurich, Switzerland
    Q J Nucl Med 47:149-61. 2003
    ....